Your browser doesn't support javascript.
loading
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
You, Benoit; Van Wagensveld, Lilian; Tod, Michel; Sonke, Gabe S; Horlings, Hugo M; Kruitwagen, R F P M; Du Bois, Andreas; Selle, Frédéric; Perren, Timothy; Pfisterer, Jacobus; Joly, Florence; Cook, Adrian; Kaminsky, Marie Christine; Wollschlaeger, Kerstin; Lortholary, Alain; Tome, Oliver; Leary, Alexandra; Freyer, Gilles; Van Der Aa, Maaike; Colomban, Olivier.
Afiliação
  • You B; Univ Lyon; Université Claude Bernard Lyon 1; Faculté de médecine Lyon-Sud; EA UCBL/HCL 3738 CICLY; Pharmacie, Lyon, France. benoit.you@chu-lyon.fr.
  • Van Wagensveld L; Medical Oncology; Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL); CITOHL; Centre Hospitalier Lyon-Sud; GINECO, Lyon, France. benoit.you@chu-lyon.fr.
  • Tod M; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.
  • Sonke GS; Department of Obstetrics and Gynecology, Maastricht University Medical Centre, Maastricht, the Netherlands; GROW, School for Oncology and Developmental Biology, Maastricht, the Netherlands.
  • Horlings HM; Univ Lyon; Université Claude Bernard Lyon 1; Faculté de médecine Lyon-Sud; EA UCBL/HCL 3738 CICLY; Pharmacie, Lyon, France.
  • Kruitwagen RFPM; Hospices Civils de Lyon; Pharmacie; Hôpital de la Croix Rousse, Lyon, France.
  • Du Bois A; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Selle F; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Perren T; Department of Obstetrics and Gynecology, Maastricht University Medical Centre, Maastricht, the Netherlands; GROW, School for Oncology and Developmental Biology, Maastricht, the Netherlands.
  • Pfisterer J; Kliniken Essen-Mitte (KEM); Essen; AGO Study Group, Essen, Germany.
  • Joly F; Groupe Hospitalier Diaconesses Croix Saint-Simon, Department of medical oncology, and GINECO, Paris, France.
  • Cook A; Leeds Institute of Medical Research at St James's University Hospital, Leeds, UK.
  • Kaminsky MC; Gynecologic Oncology Center, Herzog-Friedrich-Str. 21; 24103 Kiel; AGO Study Group, Kiel, Germany.
  • Wollschlaeger K; Centre François Baclesse; Medical Oncology Department; GINECO, Caen, France.
  • Lortholary A; Medical Research Council Clinical Trials Unit at University College London, Aviation House, 125 Kingsway, London, UK.
  • Tome O; Institut de Cancérologie de Lorraine; GINECO, Vandœuvre-lès-Nancy Cedex, France.
  • Leary A; Otto-von-Guericke University Hospital; Department of Gynecology and Obstetrics; Magdeburg; AGO Study Group, Magdeburg, Germany.
  • Freyer G; Hôpital privé du confluent, GINECO, Nantes, France.
  • Van Der Aa M; ViDia Christliche Kliniken Karlsruhe; Department of Gynecology and Obstetrics; Karlsruhe; AGO Study Group, Karlsruhe, Germany.
  • Colomban O; Institut Gustave Roussy, GINECO, Villejuif, France.
Br J Cancer ; 127(1): 79-83, 2022 07.
Article em En | MEDLINE | ID: mdl-35361918
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article